email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2611 - 2625
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
Lee's Pharma Enters $22.5 Million Deal for AI-Discovered Preclinical Molecule
$5.00
Available
Junshi Biosciences's Tuoyi is First China-Developed Anti-PD-1 Drug Approved for Marketing
$5.00
Available
Hong Kong's Aptorum Stages $12 Million US IPO for Drug Development
$5.00
Available
VoxelCloud Raises $50 Million for AI-based Clinical Decision Support
$5.00
Available
Innovent Forms Three-Drug $391.5 Million Collaboration with Incyte
$5.00
Available
I-Mab Out-Licenses Rights for Diabetes Drug to CSPC for $22 Million
$5.00
Available
Cerveau Announces Singapore Test of Neuro PET Imaging Agent
$5.00
Available
WuXi AppTec Completes Hong Kong IPO; Finishes First Trading Session Unchanged
$5.00
Available
Innovent Sees Positive Data from China Phase III Trial of Avastin Biosimilar
$5.00
Available
Zai Lab's NDA for PARP Inhibitor Accepted for China Review
$5.00
Available
Lonza to Build Biologics CDMO in China Using GE's Prefabricated Factory
$5.00
Available
Shanghai Junshi Bioscience to Raise $414 Million in Hong Kong IPO
$5.00
Available
WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics
$5.00
Available
WuXi Biologics Forms BiSpecifics Collaboration with Brii Bio
$5.00
Available
HiFiBiO Forms JV to Develop Novel Cancer Research
$5.00
Available